An accurate estimation of progression risk in patients with prostate cancer (PCa) amenable to active surveillance (AS) is still an unmet need.
Among available biomarkers, we considered Prolaris cell-cycle progression (CCP) test, "triple hit" phenotype (ERG overexpression, PTEN and prostein expression loss) and elevated expression levels of TMPRSS2-ERG gene fusions.
